1Chakrabarty AM.Microorganisms and cancer:Quest for a therapy[J].Journal of Bac Tcriology,2003,185:2683-2686.
2Ellebaek E,Andersen MH,Svane IM,et al.Immunotherapy formetastatic colorectal cancer:Present status and new options[J].ScandJ Gastroenterol,2012,47(3):315-324.
3Shurin MR,Naidi Tch H,Zhong H,et al.Regulatory dendritic cells:new targets for cancer immunotherapy[J].Cancer Biology&Therapy,2011,1l:988-992.
4Sabado RL,Bhardwaj N.Dendritic cell immunotherapy[J].Ann N Y Acad Sci,2013,1284(1):31-45.
6Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer[J].N Engl J Med,2004,351:337-345.
7Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck[J].N Engl J Med,2006,354:567-578.
8Sandler A,Gray R,Perry MC,et al.Paclitaxel carboplatin alone or with bevacizumab for non small cell lung cancer[J].N Engl J Med,2006,355:2542-2550.
9Zhao H,Fan Y,Li H,et al.Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma:A retrospective study of 165patients[J].Cancer Biother Radiopharm,2013,28(4):303-309.
